Shat­tuck Labs cuts CD47 pro­gram and 40% of work­force as it fo­cus­es on IBD drug

Shat­tuck Labs is lay­ing off 40% of its work­force and dis­con­tin­u­ing its CD47 pro­gram in acute myeloid leukemia and high­er-risk myelodys­plas­tic syn­dromes fol­low­ing dis­ap­point­ing ear­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER